Patents by Inventor Mark B. Roth

Mark B. Roth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12016880
    Abstract: The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: June 25, 2024
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Mark B. Roth, Michael L. Morrison, Akiko Iwata
  • Publication number: 20220387483
    Abstract: The present invention relates to the use of iodide compounds, to treat and prevent cachexia and cardiotoxicity resulting from treatment with an anti-cancer therapy.
    Type: Application
    Filed: November 3, 2020
    Publication date: December 8, 2022
    Inventors: Stephen A. HILL, Michael Andrew INSKO, Michael L. MORRISON, Akiko IWATA, Mark B. ROTH
  • Publication number: 20220313730
    Abstract: The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    Type: Application
    Filed: December 30, 2021
    Publication date: October 6, 2022
    Inventors: Mark B. ROTH, Michael L. MORRISON, Akiko IWATA
  • Publication number: 20210252047
    Abstract: The present invention relates to the use of halogen compounds, including iodide, to treat and prevent Post-intensive care syndrome and skeletal muscle tissue damage resulting from an injury or disease.
    Type: Application
    Filed: June 7, 2019
    Publication date: August 19, 2021
    Inventors: Stephen A. HILL, Mark B. Roth, John W. LANGSTON, Michael L. MORRISON, Akiko IWATA, Michael Andrew INSKO
  • Publication number: 20200096496
    Abstract: The present invention relates to methods for measuring a concentration of iodide in a plasma sample obtained from a subject by removing an amount of protein from the plasma sample, e.g. by precipitating protein from the plasma sample, and then measuring the concentration of the iodide in the plasma sample with ion chromatography.
    Type: Application
    Filed: June 14, 2018
    Publication date: March 26, 2020
    Inventors: Emily VANDENEKART, Mark B. Roth
  • Publication number: 20200016194
    Abstract: The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: January 16, 2020
    Inventors: Mark B. Roth, Michael L. Morrison, Akiko Iwata
  • Patent number: 10201570
    Abstract: The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: February 12, 2019
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Michael L. Morrison, Akiko Iwata
  • Publication number: 20160361356
    Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 15, 2016
    Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
  • Publication number: 20160346323
    Abstract: The present invention relates to the use of halogen compounds, including iodide, and chalcogenide compounds, including iodide, sulfide and selenide, to treat and prevent diseases and injuries. The present invention further relates to compositions comprising a halogen compound and/or a chalcogenide compound, including pharmaceutical compositions, as well as methods of manufacturing such compounds and administering such compositions to subjects in need thereof.
    Type: Application
    Filed: February 10, 2015
    Publication date: December 1, 2016
    Inventors: Mark B. ROTH, Michael L. MORRISON, Akiko IWATA
  • Publication number: 20150290240
    Abstract: This invention relates to compositions comprising chalcogenides in a reduced form, related methods of producing compositions comprising chalcogenides in a reduced form, devices for delivering a reduced form of a compound to a subject, as well as to methods for treating or preventing injuries or disease using a composition comprising a chalcogenide in a reduced form.
    Type: Application
    Filed: June 12, 2013
    Publication date: October 15, 2015
    Inventors: Mark B. Roth, Michael L. Morrison, Akiko Iwata
  • Publication number: 20150164064
    Abstract: The present invention concerns the use of oxygen antagonists for inducing stasis in cells, tissues, and/or organs in vivo or in an organism overall. It includes methods and apparatuses for achieving stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer is provided.
    Type: Application
    Filed: July 24, 2014
    Publication date: June 18, 2015
    Inventor: Mark B. Roth
  • Patent number: 8822535
    Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: September 2, 2014
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
  • Publication number: 20130252897
    Abstract: The present invention concerns the use of polychalcogenide compositions on cells, tissue, organs, and organisms to enhance their survivability. It includes compositions, compounds, methods, articles of manufacture and apparatuses for enhancing survivability and for protecting them from or treating them for injury or damage. In specific embodiments, there are also therapeutic methods and apparatuses for hypoxic/ischemic injury, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the polychalcogenide compositions described.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 26, 2013
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Mark B. Roth, Mike Morrison
  • Publication number: 20120282353
    Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.
    Type: Application
    Filed: March 26, 2012
    Publication date: November 8, 2012
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mark Budde
  • Publication number: 20120244067
    Abstract: The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive.
    Type: Application
    Filed: March 22, 2012
    Publication date: September 27, 2012
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Pamela A. Padilla
  • Publication number: 20120135091
    Abstract: The present invention concerns the use of active compounds, including chalcogenides and sirtuin-modulating compounds, either alone or in combination for increasing or enhancing survivability and/or longevity in biological matter. In general aspects, the chalcogenides and other active compounds may modulate one or more sirtuin proteins. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Application
    Filed: January 18, 2008
    Publication date: May 31, 2012
    Inventors: Mark B. Roth, Dana L. Miller
  • Publication number: 20120052479
    Abstract: The present invention concerns the use of oxygen antagonists for inducing stasis in tissue, including all or part of organs. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.
    Type: Application
    Filed: June 21, 2011
    Publication date: March 1, 2012
    Inventor: Mark B. Roth
  • Publication number: 20120040024
    Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Application
    Filed: July 29, 2011
    Publication date: February 16, 2012
    Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
  • Patent number: 7993681
    Abstract: The present invention concerns the use of oxygen antagonists for inducing stasis in tissue, including all or part of organs. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: August 9, 2011
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Mark B. Roth
  • Publication number: 20100021387
    Abstract: The present invention concerns compositions and methods involving incubating biological materials under hypoxic or anoxic conditions to induce stasis or suspended animation. Methods of screening for compounds that induce stasis or compounds that increase the ability to undergo stasis are included. Such methods have ramifications for preserving biological materials as well as reducing or preventing trauma to biological materials. Also contemplated are methods for screening compounds that are active or more active under hypoxic conditions than normoxic conditions. Such methods can be used to identify antitumor compounds that would operate under hypoxic conditions in which tumor cells survive.
    Type: Application
    Filed: June 4, 2009
    Publication date: January 28, 2010
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Mark B. Roth, Pamela A. Padilla